Home > Clinical Trials
Check All Search

Saved trials

COMPLETED
NCT04644237
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
152 Enrollment(s)
50 Study location(s)
INTERVENTIONAL (PHASE2)
Non-Small Cell Lung Cancer
TERMINATED
NCT05954143
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
11 Enrollment(s)
4 Study location(s)
INTERVENTIONAL (PHASE2)
Metastatic Breast Cancer


HER2-positive Breast Cancer
ACTIVE_NOT_RECRUITING
NCT05704829
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
402 Enrollment(s)
43 Study location(s)
INTERVENTIONAL (PHASE2)
HER2-positive Early Breast Cancer
RECRUITING
NCT04986579
Scalp Cooling in MBC
120 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE2)
Metastatic Breast Cancer


Chemotherapy-induced Alopecia
RECRUITING
NCT07180264
Trastuzumab Deruxtecan in Advanced Breast Cancer
118 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Advanced Breast Cancer
ACTIVE_NOT_RECRUITING
NCT04042701
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
115 Enrollment(s)
30 Study location(s)
INTERVENTIONAL (PHASE1)
Breast Cancer


Non-small Cell Lung Carcinoma
RECRUITING
NCT04553770
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
88 Enrollment(s)
9 Study location(s)
INTERVENTIONAL (PHASE2)
Early-stage Breast Cancer


Hormone Receptor Positive Breast Carcinoma


Invasive Breast Cancer


Stage II Breast Cancer


Stage IIA Breast Cancer


Stage IIB Breast Cancer


Stage III Breast Cancer
RECRUITING
NCT07025148
Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
40 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Arterial Disease (CAD)


Percutaneous Coronary Intervention (PCI)